"However, Badenoch and the shadow health secretary, Stuart Andrew, wrote to Streeting on 25 November, saying they were concerned NHS England was supporting a clinical trial involving drugs which halted natural puberty. Cass found remarkably weak evidence the drugs were effective in treating gender-related distress, adding there is no good evidence on long-term outcomes. She has said a trial is the only way forward in the attempt to understand if there are beneficial effects."
"The new trial will study the effects of puberty blockers on more than 200 children presenting with gender identity conditions as part of a wider research project on possible treatment pathways. The 10.7m study is being carried out by researchers at King's College London. Streeting's intervention came despite admitting he is deeply uncomfortable about medication which affects a natural part of our human development."
Wes Streeting called on the Conservatives to maintain the cross-party consensus on gender identity services and urged removal of heat and ideology from debate over a puberty blocker trial. Both parties had agreed to implement Hilary Cass's April 2024 recommendations for under-18 gender identity services, which included a puberty blocker trial within a broader research programme and a more holistic approach. Kemi Badenoch and Stuart Andrew expressed concern that NHS England was supporting a clinical trial involving drugs that halt natural puberty. Cass found weak evidence for effectiveness and no good long-term outcome data, saying a trial is the only way to assess benefits. The government banned the treatment outside trials. A £10.7m King's College London study will examine the effects of puberty blockers on more than 200 children presenting with gender identity conditions.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]